Acute Respiratory Failure clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Revefenacin in Acute Respiratory Insufficiency in COPD
open to eligible people ages 40 years and up
RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
Our lead scientists for Acute Respiratory Failure research studies include Igor Z Barjaktarevic, MD, PhD.